Reviva to present recover phase 3 clinical trial data for brilaroxazine in schizophrenia at the ascpt 2024 annual meeting

Cupertino, calif., march 26, 2024 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, today announced that laxminarayan bhat, ph.d., founder, president, and ceo of reviva will be presenting a poster at the american society for clinical pharmacology & therapeutics (ascpt) 2024 annual meeting, to be held in colorado springs, co, usa on march 27-29, 2023.
RVPH Ratings Summary
RVPH Quant Ranking